Advisors Asset Management Inc. increased its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 34.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,201 shares of the company's stock after purchasing an additional 4,647 shares during the period. Advisors Asset Management Inc.'s holdings in DaVita were worth $2,984,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of the company. Transcendent Capital Group LLC acquired a new position in DaVita in the third quarter worth $25,000. Blue Trust Inc. grew its holdings in DaVita by 58.6% during the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company's stock worth $29,000 after acquiring an additional 78 shares during the last quarter. Family Firm Inc. acquired a new stake in DaVita in the 2nd quarter valued at about $43,000. Versant Capital Management Inc raised its stake in shares of DaVita by 90.6% in the second quarter. Versant Capital Management Inc now owns 326 shares of the company's stock worth $45,000 after acquiring an additional 155 shares during the last quarter. Finally, Friedenthal Financial acquired a new position in shares of DaVita during the second quarter worth approximately $48,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE DVA opened at $165.51 on Friday. DaVita Inc. has a 52-week low of $98.26 and a 52-week high of $168.50. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37. The stock has a market cap of $13.57 billion, a P/E ratio of 17.85, a P/E/G ratio of 0.93 and a beta of 0.89. The firm has a 50 day moving average price of $158.31 and a 200 day moving average price of $148.36.
DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.76 by ($0.17). The firm had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. DaVita's quarterly revenue was up 4.6% on a year-over-year basis. During the same period last year, the firm earned $2.85 EPS. Analysts expect that DaVita Inc. will post 9.71 EPS for the current year.
Several research firms recently weighed in on DVA. Barclays boosted their price objective on shares of DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 31st. Bank of America raised their price target on DaVita from $139.00 to $145.00 and gave the company an "underperform" rating in a report on Wednesday, August 7th. Truist Financial upped their target price on shares of DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a research report on Monday, October 7th. Finally, UBS Group lifted their price target on shares of DaVita from $169.00 to $175.00 and gave the stock a "buy" rating in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $161.80.
Get Our Latest Stock Report on DaVita
In related news, CFO Joel Ackerman sold 64,029 shares of the firm's stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the sale, the chief financial officer now directly owns 111,481 shares in the company, valued at $17,286,243.86. This trade represents a 36.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Javier Rodriguez sold 32,176 shares of the business's stock in a transaction on Monday, August 26th. The shares were sold at an average price of $155.93, for a total transaction of $5,017,203.68. Following the completion of the sale, the chief executive officer now directly owns 905,659 shares in the company, valued at $141,219,407.87. This represents a 3.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 156,086 shares of company stock worth $24,807,161 over the last ninety days. 2.00% of the stock is currently owned by corporate insiders.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.